CClinicalTrials.gg
Not yet recruitingNCT07842523OBINUSSUpdated Sep 25, 2026

Obinutuzumab in Systemic Sclerosis

A Phase 2 interventional study of Obinutuzumab and Placebo in Systemic Sclerosis in Adults, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine if obinutuzumab is effective in systemic sclerosis

Read the detailed description

Systemic sclerosis (SSc) is a rare systemic autoimmune connective tissue-disease characterized by fibrosis, inflammation, and vasculopathy. SSc is responsible for skin fibrosis that can either be limited or diffuse. The latter phenotype of the disease is commonly associated with visceral involvement and therefore similar to graft versus host disease (GvHD) reaction. It can be life threatening in case of pulmonary or cardiovascular involvement. Nonetheless SSc remains a severe disease responsible for important disability and a poor quality of life.

B cell depletion and anti CD20 antibody (rituximab) have proven safety and efficacy in treating diffuse SSc. Obinutuzumab is a new generation anti-CD20 antibody for which efficacy and safety should be evaluated in SSc.

The OBINUSS trial was thus designed to evaluate obinutuzumab safety and efficacy in SSc.

02

Conditions studied

  • Systemic Sclerosis in Adults

Browse trials for

Keywords

  • Systemic sclerosis
  • obinutuzumab
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adult patient (>/= 18 years old),
  • Patient with a diagnosis of SSc, as defined by the American College of Rheumatology / EULAR 2013 criteria,
  • Patient with a diffuse SSc, as defined according to Leroy et al.
  • Patient with a SSc disease duration of less than 8 years (defined as time from first non-Raynaud phenomenon manifestation) or with an active SSc disease, as defined by EUSTAR disease activity score,
  • Patient with a modified Rodnan skin score (mRSS) > /= 10 and \< /= 35 units at screening,
  • Negative pregnancy test for woman of childbearing potential, woman of childbearing potential should have reliable contraception during the treatment period and up to 18 months after stopping it Women are considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. However in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient
  • Patient able to give written informed consent prior to participation in the study,
  • Affiliation to a social security scheme (profit or being entitled).
  • If patients receive mycophenolate or methotrexate for SSc, these need to be on stable dose as follows:

Mycophenolate mofetil/sodium: stable dose for at least 2 months prior to randomisation Methotrexate: stable dose and route of administration for at least 2 months prior to randomisation

- Anti-fibrotic drugs such as nintedanib is permitted

Exclusion criteria

Exclusion Criteria

  • Any B-cell depleting (e.g., anti-CD20, anti-CD19) or anti-plasma cell therapy such as, but not limited to, obinutuzumab, rituximab, ocrelizumab, ofatumumab, or bortezomib less than 9 months prior to screening or during screening. If anti-CD20 or anti-CD19 therapy has been received between 9 and 12 months prior to screening, the peripheral CD19+ B-cell count must be over 25 cells/μL
  • Cyclophosphamide, tacrolimus, ciclosporin, or voclosporin during the 2 months prior to screening or during screening
  • Any biologic therapy (other than anti-CD20, anti-CD19, or anti-plasma cell) such as, but not limited to, belimumab, ustekinumab, anifrolumab, secukinumab, or atacicept during the 2 months prior to screening or during screening
  • Inhibitors of Janus-associated kinase (JAK), Bruton's tyrosine kinase (BTK), or tyrosine kinase 2 (TYK2), including baricitinib, tofacitinib, upadacitinib, filgotinib, ibrutinib, or fenebrutinib or any investigational agent during the 2 months prior to screening or during screening
  • Any live vaccine during the 28 days prior to screening or during screening
  • High risk for clinically significant bleeding or any condition requiring plasmapheresis, IV immunoglobulin, or acute blood product transfusions during the 28 days prior the screening
  • Active infection with SARS-CoV-2 or patients not fully vaccinated following national recommendations against SARS-CoV-2
  • Significant or uncontrolled medical disease which, in the investigator's opinion, would preclude patient participation
  • HIV infection: for participants with unknown HIV status, HIV testing will be performed locally at screening if required by local regulations.
  • Active infection of any kind, excluding fungal infection of the nail beds. Any major episode of infection that also fulfills any of the following criteria:

    • Requires hospitalization during the 8 weeks prior to screening or during screening
    • Requires treatment with IV antibiotics (or anti-infectives) during the 8 weeks prior to screening or during screening
    • Requires treatment with oral antibiotics (or anti-infectives) during the 2 weeks prior to screening or during screening
    • Antibiotics or anti-infectives given in the absence of a major episode of infection are not exclusionary.
  • History of serious recurrent or chronic infection
  • History of progressive multifocal leukoencephalopathy (PML)
  • History of cancer, including solid tumors, hematological malignancies, and carcinoma in situ, within the past 5 years (Participants with non-melanomatous carcinomas of the skin that have been treated or excised and have resolved are eligible).
  • Major surgery requiring hospitalization during the 4 weeks prior to or during screening
  • Current alcohol or drug abuse or history of alcohol or drug abuse within 12 months prior to screening or during screening
  • Intolerance or contraindication to study therapies, including any of the following:

    *History of severe allergic or anaphylactic reactions to monoclonal antibodies or known hypersensitivity to any component of the obinutuzumab infusion

  • Any of the following laboratory parameters:

    • AST or ALT above 2.5 upper limit normal range
    • Neutrophils \<1.5x103/mL
    • Positive hepatitis B surface antigen (HBsAg) Participants who are HBsAg negative and hepatitis B core antibody (HBcAb) positive with no detectable hepatitis B virus (HBV) DNA are eligible but will require monthly HBV DNA monitoring until 12 months after the last dose of obinutuzumab or placebo.
    • Positive hepatitis C serology Participants with positive hepatitis C antibody test result with no detectable hepatitis C virus (HCV) RNA for at least 6 months after completion of antiviral therapy are eligible but will require monthly HCV RNA monitoring until 12 months after the last dose of obinutuzumab or placebo.
    • Hemoglobin below 7 g/dL
    • Platelet count below 50,000/L
  • Pregnant or breastfeeding woman, or woman who refuses to use an effective contraception during the study course;
  • Protected adults (including individual under legal guardianship by court order or curatorship) or adults deprived of liberty;
  • Patient participating in another investigational therapeutic study in the 3 months preceding inclusion;
  • Patients treated with CAR-T cell immunotherapy
04

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Obinutuzumab

    1000mg of i.v obinutuzumab at D1, D15 and D180

    Drug: Obinutuzumab

  • Placebo comparator
    Placebo

    1000mg of i.v placebo at D1, D15 and D180

    Drug: Placebo

Interventions

  • DrugObinutuzumab

    1000mg of i.v obinutuzumab at D1, D15 and D180

  • DrugPlacebo

    1000mg of i.v placebo at D1, D15 and D180

05

What researchers measure

Primary outcomes

  1. the percentage of patients achieving a 20% CRISS improvement from baseline in at least 3 of the 5-core set second step leasures if the Revised CRISS at 360 days.

    Time frame: 360 days

Secondary outcomes

  1. Mortality up to 360 days

    Time frame: 360 days

  2. Occurrence of Adverse Events up to 360 days

    Time frame: At 90, 180, 270 and 360 days

  3. Occurrence of Severe Adverse Events up to 360 days

    Time frame: At 90, 180, 270 and 360 days

  4. Occurrence of AE of specific interest previously mentioned

    The number of adverse events, expressed according to the Common Terminology Criteria for Adverse Events (CTCAE): CTCAE toxicity grading system per patient-year at days 180 and 360 for the following adverse events combined: death (all causes), grade 2 or higher leukopenia or thrombocytopenia, grade 3 or higher infections, hospitalization resulting either from the disease or from a complication due to the study treatment. \- Gammaglobulin and CD19 levels at 90, 180, 270 and 360 days

    Time frame: At 90, 180, 270 and 360 days

  5. Proportion of patients who achieved CRISS20 of the revised CRISS

    Time frame: At days 180 and 270

  6. Proportions of patients who achieved 30%, 40%, 50% ,60%, 70%, 80%, 90% and 100% improvement from baseline in at least 3 of the 5 core set measures of the revised CRISS

    Time frame: At days 180, 270 and 360

  7. Change in the Combined Response Index in Diffuse Systemic Sclerosis (CRISS) score.These scales range from 0 (minimum) to 1(maximum) points. Higher score mean better outcome

    Time frame: At days 180, 270 and 360

  8. Change in Physicians visual analogue scales over 18 months

    These scales range from 0 (minimum) to ten (maximum) points and will be performed at day 0, at 6, 12, and 18 months. Higher score mean better outcome. Higher score mean worse outcome

    Time frame: At 18 months

  9. Change in patients visual analogue scales over 18 month

    These scales range from 0 (minimum) to ten (maximum) points and will be performed at day 0, at 6, 12, and 18 months. Higher score mean better outcome

    Time frame: At 18 months

  10. Change in modified Rodnan skin score

    Range from 0 (minimum) to 100% (maximum). Higher score mean better outcome

    Time frame: At 90, 180, 270 and 360 days

  11. Proportion of patients with an improved modified Rodnan skin score.

    Time frame: At 90, 180, 270, 360 days

  12. Absolute change from baseline in Forced Vital Capacity FVC

    to look for a difference in Pulmonary function tests between patients treated with obinutuzumab and placebo, changes in forced vital capacity FVC and DLCO (% predicted and ml)

    Time frame: At days 180, 270, and days 360

  13. Absolute change from baseline in DLCO

    to look for a difference in Pulmonary function tests between patients treated with obinutuzumab and placebo, changes in forced vital capacity FVC and DLCO (% predicted and ml)

    Time frame: At day 180, 270 and day 360

  14. Proportion of patients with an active disease according to the EUSTAR SSc activity score.

    Time frame: At 90, 180, 270 and 360 days.

  15. Time to treatment failure.

    Defined as the time to one of the following events (whichever occurs first) occurring over the 48 weeks: death, absolute decline in %-predicted FVC \>/= 10 relative to baseline, \>/= 25% increase in mRSS and an increase in mRSS of 5 points, initiation or dose change of MTX/MMF due to clinically significant deterioration.

    Time frame: Over the 48 weeks

  16. Change in skin transcriptome.

    According to Khanna et al. Arthritis Rheumatol. 2019 Dec 10;72(1):125-136

    Time frame: At 360 days

  17. Analysis of the mouth opening trajectory

    Time frame: At days 0, 90, 180, 270 and 360

  18. SF-36 scale

    range from 0 (minimum) to 100 (maximum) points and will be performed at day 0, at 6, 12, and 18 months. Higher score mean better outcome

    Time frame: At day 0, 90, 180, 270 and day 360

  19. EQ5D5L scale

    comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on a five-point scale, from 1 (no problems) to 5 (extreme problems), with higher scores reflecting worse health status. The overall EQ-5D-5L utility index is derived using the French country-specific value set, with higher utility scores reflecting better health status

    Time frame: At day 0, 90, 180, 270 and day 360

  20. HAQ-DI scale

    range from 0 (minimum) to 3 (maximum) points. Higher score mean worse outcome

    Time frame: At day 0, 90, 180, 270 and day 360.

  21. SHAQ scale

    range from 0 (minimum) to 3 (maximum) points. Higher score mean worse outcome

    Time frame: At day 0, 90, 180, 270 and day 360.

  22. Saint Georges Respiratory Hospital Questionnaire (SGRH)

    range from 0 (minimum) to one hundred (maximum) points. Higher score mean worse outcome

    Time frame: At day 0, 90, 180, 270 and day 360

  23. King Brief's Interstitial Lung Disease questionnaire (KBILD)

    range from 0 (minimum) to 100 (maximum) points. Higher score mean better outcome

    Time frame: At day 0, 90, 180, 270 and day 360

  24. Scleroderma skin patients reported outcome (SSPRO)

    range from 0 (minimum) to 108 (maximum) points. Higher score mean worse outcome

    Time frame: At day 0, 90, 180, 270 and day 360

  25. PRO self-administered questionnaire (ScleroID)

    range from 0 (minimum) to 10 (maximum) points. Higher score mean worse outcome

    Time frame: At day 0, 90, 180, 270 and day 360

06

Study locations

1 site
  • Hôpital Cochin
    Paris, Île-de-France Region 75014, France
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07842523
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
URC-CIC Paris Descartes Necker Cochin
Responsible party
Sponsor
First posted
Sep 25, 2026
Start date
Nov 2026 (estimated)
Primary completion
Dec 2029 (estimated)
Completion
Jun 2030 (estimated)
Last update
Sep 25, 2026

Study contacts

Benjamin CHAIGNE, MD
Contact
benjamin.chaigne@aphp.fr
01 58 41 41 17 ext. +33
Adèle BELLINO
Contact
adele.bellino@aphp.fr
01 71 76 07 57 ext. +33
Luc MOUTHON, MD / PhD
study chair · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion